Information Provided By:
Fly News Breaks for July 28, 2015
AGN, MYL, TEVA
Jul 28, 2015 | 06:06 EDT
BMO Capital analyst David Maris upgraded Teva (TEVA) to Outperform after the company reached a deal to buy Allergan's (AGN) generics business for $40.5B and dropped its proposal to acquire Mylan (MYL). The acquisition looks "very positive" high accretion and significant cost savings, Maris tells investors in a research note. The deal is a "much better option" than Mylan and brings Teva a leading pipeline of generics, Maris writes. He raised his price target for shares of Teva to $80 from $75. The stock closed yesterday up $10.22 to $72.07.
News For TEVA;MYL;AGN From the Last 2 Days
There are no results for your query TEVA;MYL;AGN